Synthetic inhibition of SREBP2 and the mevalonate pathway blocks rhabdomyosarcoma tumor growth in vitro and in vivo and promotes chemosensitization
These data suggest that the Akt1, SREBP2 and MVP axis is critical for RMS tumor growth, migration, and oxidative stress protection primarily through maintaining adequate CHO levels that enable proper intracellular signaling. Therefore, stimulating CHO depletion via SREBP2 and MVP inhibition may represent a viable option to improve the combination therapy protocol, especially in pAkt1-positive RMS.
Authors
- Silvia Codenotti
- Alessandro Fanzani (ORCID: https://orcid.org/0000-0001-7475-2668)
- Luisa Lorenzi (ORCID: https://orcid.org/0000-0003-2483-2955)
- Matteo Cassandri (ORCID: https://orcid.org/0000-0002-2919-676X)
- Francesco Marampon (ORCID: https://orcid.org/0000-0002-0588-3039)
- Maura Poli (ORCID: https://orcid.org/0000-0001-9206-8122)
- Michela Asperti
- Agostina Pietrantoni (ORCID: https://orcid.org/0000-0002-1121-4464)
Institutions
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Brescia (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1016/j.molmet.2024.102085
- Citations
- 6
- Primary Topic
- Plant biochemistry and biosynthesis
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Rally Foundation
- Associazione Italiana per la Ricerca sul Cancro